G01N 2333/70578
Ngf-receptor/tnf-receptor superfamily
Official title: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
G01N2333/70578 (Ngf-receptor/tnf-receptor superfamily) appears on 167 US grants and 371 published applications in this corpus.
Search patents in G01N- Granted patents
- 167
- Published applications
- 371
- Assignees
- 227
- Inventors
- 802
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 5 | 4 |
| 2003 | 3 | 12 |
| 2004 | 1 | 3 |
| 2005 | 2 | 14 |
| 2006 | 5 | 13 |
| 2007 | 3 | 9 |
| 2008 | 4 | 4 |
| 2009 | 3 | 10 |
| 2010 | 2 | 9 |
| 2011 | 2 | 8 |
| 2012 | 3 | 11 |
| 2013 | 1 | 7 |
| 2014 | 3 | 10 |
| 2015 | 7 | 14 |
| 2016 | 8 | 23 |
| 2017 | 10 | 17 |
| 2018 | 10 | 20 |
| 2019 | 14 | 15 |
| 2020 | 14 | 25 |
| 2021 | 9 | 19 |
| 2022 | 11 | 26 |
| 2023 | 7 | 20 |
| 2024 | 12 | 24 |
| 2025 | 13 | 32 |
| 2026 | 10 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CD40 binding molecules and uses thereof29 Sep 2026US 12,747,299 B2Memorial Sloan Kettering Cancer Center
- Composition for cancer diagnosis18 Aug 2026US 12,710,425 B2Acurasysbio Co., Ltd.
- Anti-HVEM antibodies and use thereof21 Jul 2026US 12,686,722 B24C Biomed Limited
- Biodosimetry panels and methods16 Jun 2026US 12,658,304 B2Meso Scale Technologies, LLC.
- Kidney health monitoring in hypertension patients26 May 2026US 12,638,455 B2The Regents of the University of California
- Method for discriminating mono-immunotherapy from combined immunotherapy in cancers24 Sep 2026US 2026/0287591 A1Assistance Publique-HôPitaux De Paris (Aphp)
- Anti-cd40 antibody and use thereof10 Sep 2026US 2026/0265391 A1Biotheus Inc.
- Methods for the treatment of kidney diseases or disorders20 Aug 2026US 2026/0242493 A1Eledon Pharmaceuticals, Inc.
- Kidney function biomarkers6 Aug 2026US 2026/0227415 A1Meso Scale Technologies, LLC.
- Hydrogel bead-based platform for high throughput screening of immunomodulatory peptides and designer peptides for dendritic cells/macrophage reprogramming30 Jul 2026US 2026/0219276 A1The Hong Kong University of Science and Technology
Most cited
By later US patents
- Marker associated with non-alcoholic steatohepatitis95US 9,060,981 B2Mochida Pharmaceutical Co., Ltd. · 2015
- Antibody to the human OX40 receptor74US 7,550,140 B2Crucell Holland B. V. · 2009
- β2-adrenergic receptor agonists59US 6,541,669 B1Theravance, Inc. · 2003
- Agonistic binding molecules to the human OX40 receptor44US 8,133,983 B2Crucell Holland B. V. · 2012
- Humanized antibodies to human gp39, compositions containing thereof35US 6,001,358 AIDEC Pharmaceuticals Corporation · 1999